These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 24650244)

  • 1. Gastrodia elata Blume alleviates L-DOPA-induced dyskinesia by normalizing FosB and ERK activation in a 6-OHDA-lesioned Parkinson's disease mouse model.
    Doo AR; Kim SN; Hahm DH; Yoo HH; Park JY; Lee H; Jeon S; Kim J; Park SU; Park HJ
    BMC Complement Altern Med; 2014 Mar; 14():107. PubMed ID: 24650244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological antagonism of histamine H2R ameliorated L-DOPA-induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD.
    Ahmed MR; Jayakumar M; Ahmed MS; Zamaleeva AI; Tao J; Li EH; Job JK; Pittenger C; Ohtsu H; Rajadas J
    Neurobiol Aging; 2019 Sep; 81():177-189. PubMed ID: 31306812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Pavón N; Martín AB; Mendialdua A; Moratalla R
    Biol Psychiatry; 2006 Jan; 59(1):64-74. PubMed ID: 16139809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of a combination treatment of KD5040 and
    Ahn S; Song TJ; Park SU; Jeon S; Kim J; Oh JY; Jang J; Hong S; Song MA; Shin HS; Jung YR; Park HJ
    BMC Complement Altern Med; 2017 Apr; 17(1):220. PubMed ID: 28424060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK
    BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Spinnewyn B; Mautino G; Marin JG; Rocher MN; Grandoulier AS; Ferrandis E; Auguet M; Chabrier PE
    Neuropharmacology; 2011 Mar; 60(4):692-700. PubMed ID: 21129389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Zhang H; Ma L; Wang F; Chen J; Zhen X
    Neuropharmacology; 2007 Jul; 53(1):125-33. PubMed ID: 17553535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Francardo V; Recchia A; Popovic N; Andersson D; Nissbrandt H; Cenci MA
    Neurobiol Dis; 2011 Jun; 42(3):327-40. PubMed ID: 21310234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadd45β ameliorates L-DOPA-induced dyskinesia in a Parkinson's disease mouse model.
    Park HY; Ryu YK; Kim YH; Park TS; Go J; Hwang JH; Choi DH; Rhee M; Lee CH; Kim KS
    Neurobiol Dis; 2016 May; 89():169-79. PubMed ID: 26875664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.
    Solís O; García-Montes JR; Garcia-Sanz P; Herranz AS; Asensio MJ; Kang G; Hiroi N; Moratalla R
    Neurobiol Dis; 2017 Jun; 102():133-139. PubMed ID: 28315782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonergic Regulation of Synaptic Dopamine Levels Mitigates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
    Chen YH; Kuo TT; Wang V; Cheng PW; Huang EY; Ma KH; Greig NH; Olson L; Hoffer BJ; Tseng KY
    J Parkinsons Dis; 2024; 14(5):941-964. PubMed ID: 38905058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Striatal inhibition of PKA prevents levodopa-induced behavioural and molecular changes in the hemiparkinsonian rat.
    Lebel M; Chagniel L; Bureau G; Cyr M
    Neurobiol Dis; 2010 Apr; 38(1):59-67. PubMed ID: 20060905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA-Induced Dyskinesia and ∆FosB Expression.
    Feyder M; Södersten E; Santini E; Vialou V; LaPlant Q; Watts EL; Spigolon G; Hansen K; Caboche J; Nestler EJ; Fisone G
    Biol Psychiatry; 2016 Mar; 79(5):362-371. PubMed ID: 25193242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
    Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM
    Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal tyrosine hydroxylase-positive neurons are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice.
    Keber U; Klietz M; Carlsson T; Oertel WH; Weihe E; Schäfer MK; Höglinger GU; Depboylu C
    Neuroscience; 2015 Jul; 298():302-17. PubMed ID: 25892702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression.
    Padovan-Neto FE; Ferreira NR; de Oliveira-Tavares D; de Aguiar D; da Silva CA; Raisman-Vozari R; Del Bel E
    Neurosci Lett; 2013 Apr; 541():126-31. PubMed ID: 23428503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrastriatal injection of ionomycin profoundly changes motor response to l-DOPA and its underlying molecular mechanisms.
    Han C; Nie S; Chen G; Ma K; Xiong N; Zhang Z; Xu Y; Wang T; Papa SM; Cao X
    Neuroscience; 2017 Jan; 340():23-33. PubMed ID: 27771532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
    Thornton E; Hassall MM; Corrigan F; Vink R
    Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.